MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
MoonLake Immunotherapeutics
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$9.75+0.20 (+2.09%)
Close on Oct 19, 2026
- Market cap
- $720.67M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
86.3%
73M of 85M shares
Institutional holders
173
44 new, 15 sold out
Net institutional buying
14M
In Q2 2026
Insider trades, 12 months
0 buys · 27 sales
Net sold $83.03M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| David Kroin | 7,999,025 | 9.74% | 13G (passive) amendment | Jun 30, 2026 |
| Abigail P. Johnson | 5,703,049 | 9.00% | 13G (passive) amendment | Jun 30, 2025 |
| Bihua Chen | 4,480,433 | 6.25% | 13G (passive) amendment | Mar 31, 2026 |
| T. Rowe Price Investment Management, Inc. | 4,280,624 | 5.30% | 13G (passive) | Jun 30, 2026 |
| Bvf Inc/Il | 19,751,284 | 27.70% | 13D (active) amendment | Nov 6, 2025 |
| Bvf Partners L P/Il | 16,001,284 | 19.70% | 13D (active) amendment | Jun 25, 2026 |
| Lampert Mark N | 16,001,284 | 22.30% | 13D (active) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MLTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Bvf Inc/Il | 16,001,284 | 18.80% | $311.54M | – | 7.97% |
| Deep Track Capital, LP | 6,999,025 | 8.22% | $136.27M | +590,162 | 1.98% |
| T. Rowe Price Investment Management, Inc. | 4,280,624 | 5.03% | $83.34K | New | 0.05% |
| D. E. Shaw & Co., Inc. | 3,365,507 | 3.95% | $65.53M | +974,846 | 0.03% |
| Cormorant Asset Management, LP | 3,205,433 | 3.77% | $62.41M | −1,275,000 | 3.20% |
| Jupiter Topco LLC | 3,085,906 | 3.63% | $60.08M | New | 0.02% |
| Logos Global Management LP | 2,675,000 | 3.14% | $52.08M | +1,175,000 | 2.24% |
| Weiss Asset Management LP | 2,581,813 | 3.03% | $50.27M | +873,485 | 0.53% |
| Citadel Advisors LLC | 1,972,893 | 2.32% | $38.41M | +649,165 | 0.00% |
| Two Sigma Investments, LP | 1,715,349 | 2.02% | $33.40M | +593,037 | 0.02% |
| Mpm Bioimpact LLC | 1,606,967 | 1.89% | $31.29M | −204,115 | 1.91% |
| Vivo Capital, LLC | 1,400,000 | 1.64% | $27.26M | +400,000 | 2.49% |
| JPMorgan Chase & Co | 1,386,422 | 1.63% | $27.60M | +297,908 | 0.00% |
| Point72 Asset Management, L.P. | 1,158,732 | 1.36% | $22.56M | −209,786 | 0.02% |
| BlackRock, Inc. | 1,094,791 | 1.29% | $21.32M | +72,940 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 1,041,527 | 1.22% | $20.28K | −253,334 | 0.00% |
| Balyasny Asset Management L.P. | 912,715 | 1.07% | $17.77M | −152,895 | 0.02% |
| Great Point Partners LLC | 855,813 | 1.01% | $16.66M | +355,813 | 3.15% |
| Jane Street Group, LLC | 853,386 | 1.00% | $16.62M | +399,761 | 0.00% |
| Candriam S.C.A. | 769,766 | 0.90% | $14.97M | −48,360 | 0.07% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 173 | 73M | 86.3% | 44 / 72 | 44 / 15 | 21M | 7M |
| Q1 2026 | 147 | 63M | 74.3% | 40 / 50 | 43 / 21 | 18M | 11M |
| Q4 2025 | 130 | 56M | 66.2% | 47 / 55 | 23 / 46 | 27M | 8M |
| Q3 2025 | 133 | 38M | 44.2% | 49 / 33 | 41 / 45 | 9M | 30M |
| Q2 2025 | 129 | 59M | 68.9% | 23 / 36 | 52 / 27 | 5M | 6M |
| Q1 2025 | 135 | 60M | 70.6% | 37 / 32 | 42 / 15 | 4M | 6M |
| Q4 2024 | 114 | 63M | 74.3% | 22 / 46 | 32 / 13 | 5M | 4M |
| Q3 2024 | 108 | 62M | 73.0% | 18 / 51 | 23 / 19 | 6M | 5M |
| Q2 2024 | 110 | 62M | 72.3% | 22 / 36 | 39 / 23 | 6M | 5M |
| Q1 2024 | 113 | 60M | 70.4% | 21 / 43 | 38 / 33 | 5M | 5M |
| Q4 2023 | 125 | 60M | 70.1% | 37 / 52 | 32 / 28 | 8M | 5M |
| Q3 2023 | 118 | 56M | 66.4% | 47 / 31 | 26 / 11 | 5M | 4M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MLTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Capital Appreciation Fund | 1,614,289 | 1.90% | $31.43M | 0.04% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 918,586 | 1.08% | $17.88M | 0.17% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 792,072 | 0.93% | $15.42M | 0.13% | Jun 30, 2026 |
| JNL/T. Rowe Price Capital Appreciation Fund | 350,134 | 0.41% | $6.82M | 0.04% | Jun 30, 2026 |
| T. Rowe Price Capital Appreciation Equity ETF | 167,768 | 0.20% | $3.27M | 0.04% | Jun 30, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 161,391 | 0.19% | $3.10M | 0.05% | May 29, 2026 |
| Vy(R) T. Rowe Price Capital Appreciation Portfolio | 160,298 | 0.19% | $3.12M | 0.04% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 143,558 | 0.17% | $2.75M | 0.05% | May 31, 2026 |
| Penn Series Flexibly Managed Fund | 111,792 | 0.13% | $2.18M | 0.04% | Jun 30, 2026 |
| Nomura Healthcare Fund | 110,000 | 0.13% | $2.14M | 0.29% | Jun 30, 2026 |
| JNL Multi-Manager Small Cap Value Fund | 109,447 | 0.13% | $2.13M | 0.11% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 94,919 | 0.11% | $1.82M | 0.01% | May 31, 2026 |
| Invesco Dorsey Wright SmallCap Momentum ETF | 80,780 | 0.09% | $1.55M | 0.37% | May 31, 2026 |
| ALPS Medical Breakthroughs ETF | 73,934 | 0.09% | $1.42M | 0.88% | May 31, 2026 |
| iShares ESG Aware MSCI USA Small-Cap ETF | 65,400 | 0.08% | $1.25M | 0.05% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| da Silva Jorge Santos | Chief Executive Officer, Director | 2,774,893 | 3.26% | Jul 13, 2026 |
| Kristian Reich | Chief Scientific Officer | 2,746,587 | 3.23% | Jul 29, 2026 |
| Matthias Bodenstedt | Chief Financial Officer | 1,115,435 | 1.31% | Jun 23, 2026 |
| I. Gp Llc Bvf | Director, 10% owner | 10,235,089 | 12.03% | Jun 22, 2026 |
| Value Fund Ii Lp Biotechnology | Director | 11,265,678 | 13.24% | Jun 22, 2026 |
| Mark N. Lampert | Director, 10% owner | 1,039,238 | 1.22% | Jun 22, 2026 |
| Value Trading Fund OS LP Biotechnology | Director | – | – | Jun 22, 2026 |
| Partners L. P/Il Bvf | Director, 10% owner | – | – | Jun 22, 2026 |
| Value Fund L. P. Biotechnology | Director, 10% owner | – | – | Jun 22, 2026 |
| Partners OS Ltd. BVF | Director | 6,599,722 | 7.75% | Jun 22, 2026 |
| Ii Gp Llc Bvf | Director | – | – | Jun 22, 2026 |
| Inc/Il Bvf | Director, 10% owner | 1,287,768 | 1.51% | Jun 22, 2026 |
| Gp Holdings Llc Bvf | Director, 10% owner | 9,005,700 | 10.58% | Jun 22, 2026 |
| Andrew John Phillips | Director | – | – | Jun 18, 2026 |
| Catherine Moukheibir | Director | 23,500 | 0.03% | Jun 18, 2026 |
| Ramnik Xavier | Director | – | – | Jun 18, 2026 |
| Spike Loy | Director | – | – | Jun 18, 2026 |
| Simon Sturge | Director | 171,980 | 0.20% | Jun 9, 2025 |
| Cormorant Private Healthcare Fund II, LP | – | 8,494,151 | 9.98% | Oct 1, 2025 |
| Private Healthcare Fund IV LP Cormorant | – | 8,435,312 | 9.91% | Oct 1, 2025 |
| Cormorant Global Healthcare Master Fund, LP | – | 1,994,173 | 2.34% | Oct 1, 2025 |
| Private Healthcare Fund III LP Cormorant | – | – | – | Oct 1, 2025 |
| Cormorant Asset Management, LP | – | – | – | Oct 1, 2025 |
| Bihua Chen | – | 4,927,100 | 5.79% | Oct 1, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kristian Reich Chief Scientific Officer | Jul 27, 2026 | Sale(10b5-1 plan) | −1,100 | $20.00 | $22.00K | 2,711,198 |
| Kristian Reich Chief Scientific Officer | Jul 22, 2026 | Sale(10b5-1 plan) | −2,448 | $20.00 | $48.96K | 2,712,298 |
| Kristian Reich Chief Scientific Officer | Jul 21, 2026 | Sale(10b5-1 plan) | −50,000 | $20.02 | $1.00M | 2,714,746 |
| Kristian Reich Chief Scientific Officer | Jul 20, 2026 | Sale(10b5-1 plan) | −43,700 | $20.09 | $877.93K | 2,764,746 |
| Kristian Reich Chief Scientific Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −16,105 | $20.01 | $322.26K | 2,808,446 |
| da Silva Jorge Santos Chief Executive Officer, Director | Jul 10, 2026 | Sale(10b5-1 plan) | −68,289 | $20.02 | $1.37M | 2,774,893 |
| da Silva Jorge Santos Chief Executive Officer, Director | Jul 9, 2026 | Sale(10b5-1 plan) | −33,936 | $20.01 | $679.06K | 2,843,182 |
| da Silva Jorge Santos Chief Executive Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −47,775 | $20.03 | $956.93K | 2,877,118 |
| Matthias Bodenstedt Chief Financial Officer | Jun 22, 2026 | Sale(10b5-1 plan) | −39,120 | $22.04 | $862.20K | 1,115,435 |
| Matthias Bodenstedt Chief Financial Officer | Jun 18, 2026 | Sale(10b5-1 plan) | −2,794 | $19.60 | $54.76K | 1,154,555 |
| Matthias Bodenstedt Chief Financial Officer | Jun 17, 2026 | Sale(10b5-1 plan) | −15,082 | $19.68 | $296.81K | 1,157,349 |
| Kristian Reich Chief Scientific Officer | Jun 17, 2026 | Sale(10b5-1 plan) | −50,000 | $19.43 | $971.50K | 2,824,551 |
| Kristian Reich Chief Scientific Officer | Jun 16, 2026 | Sale(10b5-1 plan) | −50,000 | $18.70 | $935.00K | 2,874,551 |
| Kristian Reich Chief Scientific Officer | Jun 15, 2026 | Sale(10b5-1 plan) | −50,000 | $18.89 | $944.50K | 2,924,551 |
| Matthias Bodenstedt Chief Financial Officer | May 11, 2026 | Sale(10b5-1 plan) | −13,653 | $20.02 | $273.33K | 1,172,431 |
| Matthias Bodenstedt Chief Financial Officer | Apr 14, 2026 | Sale(10b5-1 plan) | −2,426 | $19.56 | $47.45K | 1,186,084 |
| da Silva Jorge Santos Chief Executive Officer, Director | Apr 13, 2026 | Sale | −51,873 | $18.23 | $945.64K | 2,924,893 |
| da Silva Jorge Santos Chief Executive Officer, Director | Apr 10, 2026 | Sale | −98,127 | $18.41 | $1.81M | 2,976,766 |
| Matthias Bodenstedt Chief Financial Officer | Apr 10, 2026 | Sale(10b5-1 plan) | −1,925 | $19.51 | $37.56K | 1,188,510 |
| Matthias Bodenstedt Chief Financial Officer | Apr 9, 2026 | Sale(10b5-1 plan) | −85,870 | $18.94 | $1.63M | 1,190,435 |
| Mark N. Lampert Director, 10% owner | Mar 31, 2026 | Sale | −248,530 | $16.79 | $4.17M | 1,039,238 |
| Mark N. Lampert Director, 10% owner | Mar 31, 2026 | Sale | −1,569,116 | $16.79 | $26.35M | 6,599,722 |
| Mark N. Lampert Director, 10% owner | Mar 31, 2026 | Sale | −1,932,354 | $16.79 | $32.44M | 8,302,735 |
| Matthias Bodenstedt Chief Financial Officer | Jan 7, 2026 | Award | +354,296 | – | – | 1,276,305 |
| Kristian Reich Chief Scientific Officer | Dec 19, 2025 | Conversion | +35,389 | – | – | 35,389 |
| Kristian Reich Chief Scientific Officer | Dec 19, 2025 | Returned to company | −35,389 | – | – | 0 |
| da Silva Jorge Santos Chief Executive Officer, Director | Dec 19, 2025 | Conversion | +196,316 | – | – | 3,074,893 |
| da Silva Jorge Santos Chief Executive Officer, Director | Dec 19, 2025 | Returned to company | −196,316 | – | – | 0 |
| Matthias Bodenstedt Chief Financial Officer | Dec 19, 2025 | Returned to company | −294,473 | – | – | 0 |
| Matthias Bodenstedt Chief Financial Officer | Dec 19, 2025 | Conversion | +294,473 | – | – | 922,009 |
| da Silva Jorge Santos Chief Executive Officer, Director | Dec 9, 2025 | Sale | −70,000 | $14.49 | $1.01M | 2,878,577 |
| Kristian Reich Chief Scientific Officer | Dec 9, 2025 | Sale | −72,908 | $14.43 | $1.05M | 0 |
| da Silva Jorge Santos Chief Executive Officer, Director | Dec 8, 2025 | Sale | −130,000 | $15.08 | $1.96M | 2,948,577 |
| Kristian Reich Chief Scientific Officer | Dec 8, 2025 | Sale | −130,000 | $15.08 | $1.96M | 72,908 |
| Matthias Bodenstedt Chief Financial Officer | Oct 8, 2025 | Buy | +10,870 | $9.09 | $98.81K | 627,536 |
| Cormorant Global Healthcare Master Fund, LP – | Sep 30, 2025 | Sale | −5,827 | $6.96 | $40.56K | 1,994,173 |
| Cormorant Global Healthcare Master Fund, LP – | Sep 29, 2025 | Sale | −2,800,000 | $6.61 | $18.51M | 2,000,000 |
| Cormorant Global Healthcare Master Fund, LP – | Sep 29, 2025 | Sale | −3,390,943 | $7.58 | $25.70M | 4,800,000 |
| Cormorant Global Healthcare Master Fund, LP – | Sep 29, 2025 | Sale | −70,748 | $9.38 | $663.62K | 8,423,403 |
| Cormorant Global Healthcare Master Fund, LP – | Sep 29, 2025 | Sale | −232,460 | $8.40 | $1.95M | 8,190,943 |
| Kristian Reich Chief Scientific Officer | Sep 2, 2025 | Conversion | +48,978 | – | – | 202,908 |
| Kristian Reich Chief Scientific Officer | Sep 2, 2025 | Returned to company | −48,978 | – | – | 35,389 |
| Catherine Moukheibir Director | Jul 3, 2025 | Option exercise | +23,500 | – | – | 23,500 |
| Catherine Moukheibir Director | Jul 3, 2025 | Sale | −23,500 | $48.79 | $1.15M | 0 |
| da Silva Jorge Santos Chief Executive Officer, Director | Feb 27, 2025 | Award | +95,763 | – | – | 3,078,577 |
| Matthias Bodenstedt Chief Financial Officer | Feb 27, 2025 | Award | +95,763 | – | – | 616,666 |
| Kristian Reich Chief Scientific Officer | Jan 20, 2025 | Conversion | +111,949 | – | – | 153,930 |
| Kristian Reich Chief Scientific Officer | Jan 20, 2025 | Returned to company | −111,949 | – | – | 84,367 |
| Simon Sturge Director | Oct 4, 2024 | Sale | −171,000 | $53.72 | $9.19M | 171,980 |
| I. Gp Llc Bvf Director, 10% owner | Oct 4, 2024 | Sale | −1,030,589 | $50.00 | $51.53M | 10,235,089 |
| I. Gp Llc Bvf Director, 10% owner | Oct 4, 2024 | Sale | −132,549 | $50.00 | $6.63M | 1,287,768 |
| I. Gp Llc Bvf Director, 10% owner | Oct 4, 2024 | Sale | −836,862 | $50.00 | $41.84M | 8,168,838 |
| da Silva Jorge Santos Chief Executive Officer, Director | Feb 29, 2024 | Sale(10b5-1 plan) | −4,740 | $55.89 | $264.92K | 2,982,814 |
| da Silva Jorge Santos Chief Executive Officer, Director | Feb 28, 2024 | Sale(10b5-1 plan) | −56,065 | $55.00 | $3.08M | 2,987,554 |
| Kristian Reich Chief Scientific Officer | Feb 28, 2024 | Sale(10b5-1 plan) | −31,910 | $55.00 | $1.76M | 2,925,573 |
| Kristian Reich Chief Scientific Officer | Feb 28, 2024 | Sale(10b5-1 plan) | −28,090 | $55.00 | $1.54M | 41,981 |
| da Silva Jorge Santos Chief Executive Officer, Director | Feb 27, 2024 | Sale(10b5-1 plan) | −62,810 | $55.00 | $3.45M | 3,043,619 |
| Kristian Reich Chief Scientific Officer | Feb 27, 2024 | Sale(10b5-1 plan) | −29,431 | $55.00 | $1.62M | 70,071 |
| Kristian Reich Chief Scientific Officer | Feb 27, 2024 | Sale(10b5-1 plan) | −29,491 | $55.00 | $1.62M | 2,957,483 |
| da Silva Jorge Santos Chief Executive Officer, Director | Feb 21, 2024 | Sale(10b5-1 plan) | −1,125 | $55.27 | $62.18K | 3,106,429 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kristian Reich Officer | Jul 15, 2026 | 150,000 | $2.92M | Jul 15, 2026 | Exchange of shares |
| da Silva Jorge Santos Officer, CEO | Jun 30, 2026 | 150,000 | $3.00M | Jun 30, 2026 | Exchange of shares |
| Kristian Reich Officer | Jun 15, 2026 | 150,000 | $2.85M | Jun 15, 2026 | Exchange of shares |
| Pedro Santos Radeck D. Silva Jorge CEO | Apr 10, 2026 | 150,000 | $2.79M | Apr 10, 2026 | Exchange of Shares |
| Matthias Bodenstedt Officer, CFO | Apr 9, 2026 | 160,870 | $2.97M | Apr 9, 2026 | Exchange of share |
| Partners L. P/Il Bvf 10% Stockholder, Affiliate of Director | Mar 31, 2026 | 3,750,000 | $63.49M | Mar 31, 2026 | Acquired upon the automatic conversion of private shares in connection with the consummation of the Issuer's business combination on April 5, 2022. The private shares were acquired and fully paid for |
| Pedro Santos Radeck Da Silva Jorge Officer, Director, CEO | Dec 8, 2025 | 200,000 | $2.98M | Dec 8, 2025 | Exchange of Shares |
| Dieter Johannes Reich Kristian Officer, Director, Chief Scientific Officer | Dec 8, 2025 | 202,908 | $3.00M | Dec 8, 2025 | Exchange of shares |
| Catherine Moukheibir Director | Jul 3, 2025 | 23,500 | $1.15M | Jul 3, 2025 | Option Granted - 04/06/2022 |
| da Silva Jorge Santos CEO | Feb 15, 2024 | 200,000 | $12.79M | Feb 15, 2024 | Exchange of shares |
| Kristian Reich Officer, CSO | Feb 14, 2024 | 200,000 | $12.60M | Feb 14, 2024 | Exchange of shares |
| Matthias Bodenstedt Officer, CFO | Dec 20, 2023 | 5,264 | $312.00K | Dec 20, 2023 | Exchange of share |
| Matthias Bodenstedt Officer, CFO | Dec 19, 2023 | 94,736 | $5.61M | Dec 19, 2023 | Exchange of share |